| Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 148 | 2022 |
| Body mass index and complications following major gastrointestinal surgery: a prospective, international cohort study and meta‐analysis EuroSurg Collaborative, R Blanco‐Colino, S Lee, SK Kamarajah, P Vasko, ... Colorectal Disease 20 (8), O215-O225, 2018 | 56 | 2018 |
| Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study CAM Fulgenzi, J Cheon, A D'Alessio, N Nishida, C Ang, TU Marron, L Wu, ... European Journal of Cancer 175, 204-213, 2022 | 54 | 2022 |
| Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab YL Wu, CAM Fulgenzi, A D’Alessio, J Cheon, N Nishida, A Saeed, ... Cancers 14 (23), 5834, 2022 | 30 | 2022 |
| Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma B Scheiner, D Roessler, S Phen, M Lim, K Pomej, T Pressiani, ... JHEP reports 5 (1), 100620, 2023 | 21 | 2023 |
| The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together A D’Alessio, A Cammarota, MG Prete, T Pressiani, L Rimassa Current Opinion in Oncology 33 (4), 386-394, 2021 | 19 | 2021 |
| Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma M Vithayathil, A D'Alessio, CAM Fulgenzi, N Nishida, M Schönlein, ... Liver International 42 (11), 2538-2547, 2022 | 18 | 2022 |
| Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study M Persano, M Rimini, T Tada, G Suda, S Shimose, M Kudo, J Cheon, ... Journal of Cancer Research and Clinical Oncology 149 (9), 5591-5602, 2023 | 16 | 2023 |
| Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing? A Cammarota, V Zanuso, GF Manfredi, R Murphy, DJ Pinato, L Rimassa Therapeutic Advances in Medical Oncology 15, 17588359221148029, 2023 | 13 | 2023 |
| Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma A D’Alessio, A Cammarota, V Zanuso, T Pressiani, N Personeni, ... Expert review of anticancer therapy 21 (9), 927-939, 2021 | 13 | 2021 |
| Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma M Vithayathil, A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, ... Hepatology international 17 (4), 904-914, 2023 | 12 | 2023 |
| Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: Shedding light on the preclinical rationale and clinical trials A Cammarota, V Zanuso, A D’Alessio, T Pressiani, N Personeni, ... Expert Opinion on Investigational Drugs 31 (4), 401-413, 2022 | 11 | 2022 |
| The role of cabozantinib as a therapeutic option for hepatocellular carcinoma: current landscape and future challenges A D’Alessio, MG Prete, A Cammarota, N Personeni, L Rimassa Journal of Hepatocellular Carcinoma, 177-191, 2021 | 9 | 2021 |
| Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study N Personeni, L Giordano, A Michelini, A D’Alessio, A Cammarota, ... Journal of Personalized Medicine 12 (2), 204, 2022 | 5 | 2022 |
| Systemic treatment for older patients with unresectable hepatocellular carcinoma A Cammarota, A D’Alessio, T Pressiani, L Rimassa, N Personeni Drugs & Aging 38 (7), 579-591, 2021 | 5 | 2021 |
| The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials A Cammarota, V Zanuso, A D’Alessio, T Pressiani, S Bozzarelli, ... Expert Opinion on Investigational Drugs 31 (4), 425-435, 2022 | 4 | 2022 |
| Assessment and monitoring of response to systemic treatment in advanced hepatocellular carcinoma: Current insights A Cammarota, V Zanuso, T Pressiani, N Personeni, L Rimassa Journal of Hepatocellular Carcinoma, 1011-1027, 2022 | 4 | 2022 |
| A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma L Balcar, B Scheiner, CAM Fulgenzi, A D’Alessio, K Pomej, MB Roig, ... JHEP reports 6 (2), 100982, 2024 | 3 | 2024 |
| Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma S Dharmapuri, U Özbek, H Jethra, T Jun, TU Marron, A Saeed, YH Huang, ... World journal of gastrointestinal oncology 15 (11), 1900, 2023 | 3 | 2023 |
| The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab A D’Alessio, C Fulgenzi, B Scheiner, J Korolewicz, J Cheon, N Nishida, ... Journal of Hepatology 78, S575, 2023 | 2 | 2023 |
